Introduction Pelvic exenteration can be performed with curative or palliative intent for treatment of recurrent gynecologic malignancies. We evaluated progression-free survival (PFS) and overall survival (OS) in association with postoperative chemotherapy following pelvic exenteration for recurrent gynecologic malignancies.
Methods We retrospectively reviewed patients with recurrent uterine, cervical, vulvar, or vaginal carcinoma who underwent pelvic exenteration from 5/01/2005–12/31/2019. Patients were excluded if surgery was performed for palliation without recurrence. Survival was assessed for allcomers and by uterine and cervical primary sites.
Results Of 123 patients identified, 32% (39/123) were referred to medical oncology; 25 (64%) of 39 were offered and 19 (76%) of 25 received postoperative chemotherapy. Regimens included carboplatin/cisplatin and paclitaxel (n=12), another platinum doublet (n=4), or single-agent platinum (n=3). Patients who received postoperative chemotherapy, compared with those who did not, more often had positive surgical margins (21% vs. 7%, p=0.025), a uterine primary (58% vs. 18% p=0.003), and endometrioid histology (53% vs. 13% p=0.010). One patient in the no-chemotherapy group received postoperative pelvic radiation. Of the 19 patients who received postoperative chemotherapy, 7 (37%) recurred— 5 (26%) locally and 2 (11%) distantly (brain, bowel). There was no difference in 2-year PFS rate (68.4% SE ±1.1 vs. 68.9% SE ±0.05) or 2-year OS rate (78.9% SE ±1.0 vs. 74.5% SE ±0.05) between patients who did and did not undergo postoperative chemotherapy, respectively.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.